A DPYD variant (y186c) specific to individuals of african descent in a patient with life-threatening 5-fu toxic effects: Potential for an individualized medicine approach

Mayo Clinic Proceedings

Volumn 89, Issue 1, 2014, Pages 131-136

  Saif, Muhammad Wasif ^a   Lee, Adam M ^b   Offer, Steven M ^b   McConnell, Kathleen ^a   Relias, Valerie ^a   Diasio, Robert B ^b  

^a TUFTS MEDICAL CENTER   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; FLUCONAZOLE; FLUOROURACIL; FOLFOX; HEMOGLOBIN; LACTATE DEHYDROGENASE; LEVOLEUCOVORIN; OXALIPLATIN; PHOSPHORUS; POTASSIUM; RISPERIDONE; UNCLASSIFIED DRUG; VANCOMYCIN; VITAMIN K GROUP;

ADULT; AFRICAN AMERICAN; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BLOOD CLOTTING FACTOR 7 DEFICIENCY; CANCER PATIENT; CASE REPORT; CAUSE OF DEATH; CLOSTRIDIUM DIFFICILE; COLON CANCER; COLON METASTASIS; COLON PERFORATION; DEHYDRATION; DELIRIUM; DPYD GENE; ESOPHAGITIS; FEMALE; GENETIC MARKER; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTERNATIONAL NORMALIZED RATIO; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; MUCOSA INFLAMMATION; NEUTROPHIL COUNT; PAIN; PANCYTOPENIA; PARENTERAL NUTRITION; PERSONALIZED MEDICINE; PHOSPHATE BLOOD LEVEL; POTASSIUM BLOOD LEVEL; PROTHROMBIN TIME; THROMBOCYTE COUNT; UREA NITROGEN BLOOD LEVEL;

EID: 84893039495     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2013.09.008     Document Type: Article

References (28)

1. Meta-Analysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factos. J Clin Oncol. 1998;16(11):3537-3541.
2. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet. 1989;16(4):215-237.
3. Saif MW, Syrigos K, Mehra R, et al. Dihydropyrimidine dehydrogenase deficiency (DPD) in GI malignancies: experience of 4 years. Pak J Med Sci. 2007;23(6):832-839.
4. Daher GC, Harris BE, Diasio RB. Metabolism of pyrimidine analogues and their nucleosides. Pharmacol Ther. 1990;48(2): 189-222.
5. Harris BE, Song R, Soong SJ, Diasio RB. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res. 1990;50(1):197-201.
6. Harris BE, Carpenter JT, Diasio RB. Severe 5-Fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency: a potentially more common pharmacogenetic syndrome. Cancer. 1991;68(3):499-501.
7. Etienne MC, Lagrange JL, Dassonville O, et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol. 1994;12(11):2248-2253.
8. Offer SM, Wegner NJ, Fossum C, Wang K, Diasio RB. Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity. Cancer Res. 2013;73(6):1958-1968.
9. Boisdron-Celle M, Remaud G, Traore S, et al. 5-Fluorouracilrelated severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett. 2007;249(2):271-282.
10. Morel A, Boisdron-Celle M, Fey L, et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther. 2006;5(11):2895-2904.
11. Schwab M, Zanger UM, Marx C, et al; German 5-FU Toxicity Study Group. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol. 2008;26(13):2131-2138.
12. Wei XX, McLeod HL, McMurrough J, Gonzalez FJ, Fernandezsalguero P. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest. 1996;98(3):610-615.
13. Johnson MR, Wang K, Diasio RB. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin Can Res. 2002;8(3):768-774.
14. van Kuilenburg AB, Dobritzsch D, Meinsma R, et al. Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three dimensional protein structure. Biochem J. 2002;364(pt 1):157-163.
15. Offer SM, Lee AM, Mattison LK, Fossum C, Wegner NJ, Diasio RB. A DPYD variant (Y186C) in individuals of African ancestry is associated with reduced DPD enzyme activity. Clin Pharmacol Ther. 2013;94(1):158-166.
16. Mattison LK, Fourie J, Desmond RA, Modak A, Saif MW, Diasio RB. Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res. 2006;12(18):5491-5495.
17. Morsman JM, Sludden J, Ameyaw MM, et al. Evaluation of dihydropyrimidine dehydrogenase activity in South-west Asian, Kenyan and Ghanaian populations. Br J Clin Pharmacol. 2000; 50(3):269-272.
18. Ezzeldin H, Okamoto Y, Johnson MR, Diasio RB. A highthroughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency. Ann Biochem. 2000;306(1):63-73.
19. Ezzeldin H, Hoffmayer C, Soong R, et al. Simultaneous detection of variable number tandem repeats, single nucleotide polymorphisms, and allelic imbalance in the thymidylate synthase gene enhancer region using denaturing high performance liquid chromatography. Ann Biochem. 2004;334(2):276-283.
20. Gusella M, Padrini R. G>C SNP of thymidylate synthase with respect to colorectal cancer. Pharmacogenomics. 2007;8(8): 985-996.
21. Santini D, Vincenzi B, Perrone G, et al. Thymidylate synthase expression in normal colonic mucosa: a predictive marker of toxicity in colorectal cancer patients receiving 5-fluorouracil-based adjuvant chemotherapy. Oncology. 2004;67(2):135-142.
22. Pullarkat ST, Stoehlmacher J, Ghaderi V, et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J. 2001; 1(1):65-70.
23. Lecomte T, Ferraz JM, Zinzindohoué F, et al. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res. 2004;10(17):5880-5888.
24. Liu YP, Ling Y, Qi QF, et al. Genetic polymorphisms of ERCC1-118, XRCC1-399 and GSTP1-105 are associated with the clinical outcome of gastric cancer patients receiving oxaliplatin-based adjuvant chemotherapy. Mol Med Rep. 2013;7(6):1904-1911.
25. McLeod HL, Sargent DJ, Marsh S, et al. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol. 2010; 28(20):3227-3233.
26. Chen YC, Tzeng CH, Chen PM, et al. Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Sci. 2010;101(2):530-535.
27. Boige V, Mendiboure J, Pignon JP, et al. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J Clin Oncol. 2010;28(15): 2556-2564.
28. Braun MS, Richman SD, Thompson L, et al. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. J Clin Oncol. 2009;27(33):5519-5528.